80240-44-4

Basic information

• Product Name: 3H-1,2,4-Triazol-3-one, 2,4-dihydro-4-(4-methoxyphenyl)-
• CAS NO: 80240-44-4
• Molecular Formula: C9H9N3O2
• Molecular Weight: 191.189
• Mol File: 80240-44-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3H-1,2,4-Triazol-3-one, 2,4-dihydro-4-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-1,2,4-Triazol-3-one, 2,4-dihydro-4-(4-methoxyphenyl)-(80240-44-4)
• EPA Substance Registry System: 3H-1,2,4-Triazol-3-one, 2,4-dihydro-4-(4-methoxyphenyl)-(80240-44-4)

Safety Data

• Hazardous Substances Data: 80240-44-4(Hazardous Substances Data)

Upstream product

• 62774-59-8 N-(4-methoxyphenyl)hydrazinecarboxamide 
• 3473-63-0 formamidine acetic acid 
• 6294-89-9 hydrazinecarboxylic acid methyl ester 
• 104-94-9 4-methoxy-aniline 
• 149-73-5 trimethyl orthoformate 
• 126918-33-0 (1S)-1-<(2R)-2-(2,4-difluorophenyl)-2-oxiranyl>ethanol 

Downstream Products

• 1312809-85-0 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-4-(4-methoxyphenyl)-1H-1,2,4-triazol-5(4H)-one 
• 1355558-37-0 C₁₆H₁₄BrN₃O₃ 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δDual Agonists for the Treatment of Nonalcoholic Steatohepatitis

Peroxisome proliferator-activator receptors α/δ(PPARα/δ) are regarded as potential therapeutic targets for nonalcoholic steatohepatitis (NASH). However, PPARα/δdual agonist GFT-505 exhibited poor anti-NASH effects in a phase III clinical trial, probably due to its weak PPARα/δagonistic activity and poor metabolic stability. Other reported PPARα/δdual agonists either exhibited limited potency or had unbalanced PPARα/δagonistic activity. Herein, we report a series of novel triazolone derivatives as PPARα/δdual agonists. Among them, compound H11 exhibited potent and well-balanced PPARα/δagonistic activity (PPARα EC50 = 7.0 nM; PPARδEC50 = 8.4 nM) and a high selectivity over PPARγ(PPARγEC50 = 1316.1 nM) in PPAR transactivation assays. The crystal structure of PPARδin complex with H11 revealed a unique PPARδ-agonist interaction. H11, which had excellent PK properties and a good safety profile, showed potent in vivo anti-NASH effects in preclinical models. Together, H11 holds a great promise for treating NASH or other inflammatory and fibrotic diseases.

Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one

Based on the structure of the active site of cytochrome P450 14α-demethylase (CYP51) and the conclusions of the structure-activity relationships of azole antifungals, a series of 1-(2-(2,4-difluoro-phenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one of fluconazole analogs was synthesized. All compounds were characterized by IR, HRMS, 1HNMR and 13C NMR spectroscopic analysis. Results of preliminary antifungal in vitro test using eight human pathogenic species showed that some compounds displayed comparable or even better antifungal activities than reference drug fluconazole and that compound 3i exhibited significant activity against Candida albicans being worthy of further optimization.